Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1875-1882

  Takahashi, Tsuyoshi ^a   Ohtsuka, Tatsuyuki ^a   Yoshikawa, Takahiro ^b   Tatekawa, Ichiro ^b   Uno, Yasuhiro ^b   Utoh, Masahiro ^b   Yamazaki, Hiroshi ^c   Kume, Toshiyuki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MESSENGER RNA; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; PITAVASTATIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG UPTAKE; DRUG URINE LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; GASTROINTESTINAL TRACT; HALF-LIFE; HEPATOCYTES; HUMANS; LIVER; MACACA FASCICULARIS; MALE; ORGANIC ANION TRANSPORTERS; QUINOLINES; RNA, MESSENGER;

EID: 84884684859     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052753     Document Type: Article

References (39)

1. Center for Drug Evaluation and Research (CDER) (2009a) Application Number 22-363, Clinical Pharmacology and Biopharmaceutics Review(s), Part 1. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Rockville, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022363s000-ClinPharmR-P1.pdf.
2. Center for Drug Evaluation and Research (CDER) (2009b) Application Number 22-363, Clinical Pharmacology and Biopharmaceutics Review(s), Part 2. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Rockville, MD. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022363s000-ClinPharmR-P2.pdf.
3. Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [Draft Guidance], U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf.
4. Committee for Human Medicinal Products (CHMP) (2012) Guideline on the Investigation of Drug Interactions [Final], European Medicines Agency, London. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 07/WC500129606.pdf.
5. Ebeling M, Küng E, See A, Broger C, Steiner G, Berrera M, Heckel T, Iniguez L, Albert T, and Schmucki R, et al. (2011) Genome-based analysis of the nonhuman primate Macaca fascicularis as a model for drug safety assessment. Genome Res 21:1746-1756.
6. Gui C and Hagenbuch B (2010) Cloning/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classification of the canine OATP/SLCO members. Comp Biochem Physiol C Toxicol Pharmacol 151:393-399.
7. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665. (Pubitemid 38241451)
8. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, Iijima H, and Saito Y (2003) The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 19:381-389.
9. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807. (Pubitemid 41206035)
10. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146. (Pubitemid 39287793)
11. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2006) Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
12. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, and Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
13. Kalliokoski A and Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
14. Kimata H, Fujino J, Koide T, Yamada Y, Tsunenari Y, Yonemitsu M, and Yanagawa Y (1998) Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Xenobiotic Metab Dispos 13:484-498.
15. Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, and Hidalgo IJ (2012) Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 40:865-876.
16. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771. (Pubitemid 43131004)
17. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204. (Pubitemid 46174816)
18. Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, and Lavé T (2003) Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 92:1990-2007. (Pubitemid 37175630)
19. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581.
20. Maeda K and Sugiyama Y (2010) Comparison of the function of transporters involved in the hepatic and renal uptake of drugs between monkeys and humans. Pharmaceutical Society of Japan 130th Annual Meeting; 2010 March 28-30; Okayama, Japan.
21. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
22. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, and Roots I, et al. (1999) Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65:251-261. (Pubitemid 29142931)
23. Nakanishi Y, Matsushita A, Matsuno K, Iwasaki K, Utoh M, Nakamura C, and Uno Y (2010) Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab Pharmacokinet 25:290-297.
24. Ogasawara A, Kume T, and Kazama E (2007) Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410-418. (Pubitemid 46333904)
25. Ogasawara A, Utoh M, Nii K, Ueda A, Yoshikawa T, Kume T, and Fukuzaki K (2009a) Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos 37:122-128.
26. Ogasawara A, Negishi I, Kozakai K, and Kume T (2009b) In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys. Drug Metab Dispos 37:2127-2136.
27. Ohtsuka T, Yoshikawa T, Kozakai K, Tsuneto Y, Uno Y, Utoh M, Yamazaki H, and Kume T (2010) Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806-1813.
28. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, and Gibson C, et al. (2011) Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234-242.
29. Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, and Kallipatti S, et al. (2013) Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther 344:673-685.
30. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616. (Pubitemid 36152336)
31. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105. (Pubitemid 44301483)
32. Tahara H, Kusuhara H, Chida M, Fuse E, and Sugiyama Y (2006) Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 316:1187-1194. (Pubitemid 43345293)
33. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, and Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269. (Pubitemid 32846318)
34. Uno Y, Fujino H, Kito G, Kamataki T, and Nagata R (2006) CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol Pharmacol 70:477-486. (Pubitemid 44092308)
35. Uno Y, Kumano T, Kito G, Nagata R, Kamataki T, and Fujino H (2007) CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans. Xenobiotica 37:30-43. (Pubitemid 46009555)
36. Utoh M, Uno Y, Ohtsuka T, and Kume T (2012) Identification and analysis of drug transporters in cynomolgus macaques. Japanese Society for the Study of Xenobiotics (JSSX) 27th Annual Meeting; 2012 Nov 20-22; Chiba, Japan.
37. White EP, Pimprale S, Yu Z, Ketty V, Bourgea J, Patten CJ, Crespi C, and Xiao G (2006) Cloning and characterization of cynomolgus monkey and rhesus monkey organic anion transporting poloypeptide 1B3, and comparison of their function with human OATP1B3. International Society for the Study of Xenobiotics (ISSX) 14th North American Meeting; 2006 Oct 22-26; Rio Grande, PR.
38. Yamada I, Fujino H, Shimada S, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 33:789-803. (Pubitemid 36960263)
39. Yoshida K, Maeda K, and Sugiyama Y (2012) Transporter-mediated drug - drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91:1053-1064.